First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12 months and 5 years of age-Reference-Cited by-同舟云学术

First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12 months and 5 years of age

Published:2017-01 Issue:4 Volume:35 Page:596-604
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Lindgren Line M.,Tingskov Pernille N.,Justesen Annette H.,Nedergaard Bettina S.,Olsen Klaus J.,Andreasen Lars V.,Kromann Ingrid,Sørensen Charlotte,Dietrich Jes,Thierry-Carstensen Birgit

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference20 articles.

1. World Health Organisation. Polio eradication & endgame strategic plan 2013-2018. WHO Press World Health Organisation, 20 Avenue Appia, Geneva, Switzerland 2013. Available from: URL: .

2. Affordable inactivated poliovirus vaccine: strategies and progress;Okayasu;J Infect Dis,2014

3. Poliovirus vaccination options for achieving eradication and securing the endgame;Estivariz;Curr Opin Virol,2013

4. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?;Brenzel;Vaccine,2015

5. Introduction of inactivated poliovirus vaccine and switch from trivalen to bivalent oral poliovirus vaccine - worldwide, 2013–2016. MMWR Recomm Rep 2016 March 7. Vol. 64 (25). p. 699–702.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polio and Its Epidemiology;Infectious Diseases;2023

2. Poliovirus Vaccine—Inactivated;Plotkin's Vaccines;2023

3. Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine;Vaccine;2022-09

4. In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine;Vaccines;2020-10-13

5. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15–18 months;Vaccine;2020-05